The CRF1 receptor antagonist, R121919, attenuates the severity of precipitated morphine withdrawal

European Journal of Pharmacology

Volumn 571, Issue 1, 2007, Pages 17-24

  Skelton, Kelly H ^a   Oren, Dana ^a   Gutman, David A ^a   Easterling, Keith ^a   Holtzman, Stephen G ^a   Nemeroff, Charles B ^a   Owens, Michael J ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anxiety; Corticotropin releasing factor (CRF); Drug withdrawal; Opiate; Stress

Indexed keywords

3 (6 DIMETHYLAMINO 4 METHYL 3 PYRIDINYL) 7 DIPROPYLAMINO 2,5 DIMETHYLPYRAZOLO[1,5 A]PYRIMIDINE; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; MORPHINE; RNA; CORTICOTROPIN RELEASING FACTOR RECEPTOR; CRF RECEPTOR TYPE 1; MESSENGER RNA; NARCOTIC ANALGESIC AGENT; PYRIMIDINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATTENUATION; AUTONOMIC NERVOUS SYSTEM; BEHAVIOR; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; GENE EXPRESSION; HYPOTHALAMUS; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MALE; NERVE CELL; NEUROENDOCRINOLOGY; NONHUMAN; PRECIPITATION; PRIORITY JOURNAL; RAT; RATING SCALE; THALAMUS MIDLINE NUCLEUS; WITHDRAWAL SYNDROME; ANIMAL; ANIMAL BEHAVIOR; DRUG ANTAGONISM; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; HOSPITALIZATION; HYPOPHYSIS ADRENAL SYSTEM; HYPOTHALAMIC PARAVENTRICULAR NUCLEUS; HYPOTHALAMUS HYPOPHYSIS SYSTEM; IN SITU HYBRIDIZATION; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SPRAGUE DAWLEY RAT;

ANALGESICS, OPIOID; ANIMALS; BEHAVIOR, ANIMAL; GENE EXPRESSION REGULATION; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; IN SITU HYBRIDIZATION; MALE; MORPHINE; PARAVENTRICULAR HYPOTHALAMIC NUCLEUS; PITUITARY-ADRENAL SYSTEM; PYRIMIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; RNA, MESSENGER; SEVERITY OF ILLNESS INDEX; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 34548030252     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2007.05.041     Document Type: Article

References (42)

1. Adinoff B., Anton R., Linnoila M., Guidotti A., Nemeroff C.B., and Bissette G. Cerebrospinal fluid concentrations of corticotropin-releasing hormone (CRH) and diazepam-binding inhibitor (DBI) during alcohol withdrawal and abstinence. Neruopsychopharmacology 15 (1996) 288-295
2. Baldwin H.A., Rassnick S., Rivier J., Koob G.F., and Britton K.T. CRF antagonist reverses the "anxiogenic" response to ethanol withdrawal in the rat. Psychopharmacology 103 (1991) 227-232
3. Basso A.M., Spina M., Rivier J., Vale W., and Koob G.F. Corticotropin-releasing factor antagonist attenuates the "anxiogenic-like" effect in the defensive burying paradigm but not in the elevated plus-maze following chronic cocaine in rats. Psychopharmacology 145 (1999) 21-30
4. 9-41 α helical) reduces morphine withdrawal in rats. Prog. Neuropsychopharmacol. Biol. Psych. 22 (1998) 775-785
5. Contarino A., and Papaleo F. The corticotrophin-releasing factor receptor-1 pathway mediates the negative affective states of opiate withdrawal. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 18649-18654
6. Conti L.H., and Foote S.L. Reciprocal cross-desensitization of locus coeruleus electrophysiological responsivity to corticotropin-releasing factor and stress. Brain Res. 722 (1996) 19-29
7. Duman R.S., Tallman J.F., and Nestler E.J. Acute and chronic opiate-regulation of adenylate cyclase in brain: specific effects in locus coeruleus. J. Pharmacol. Exp. Ther. 246 (1988) 1033-1039
8. Ennis M., and Aston-Jones G. Activation of locus coeruleus from nucleus paragigantocellularis: a new excitatory amino acid pathway in brain. J. Neurosci. 8 (1988) 3644-3657
9. Funada M., Hara C., and Wada K. Involvement of corticotropin-releasing factor receptor subtype 1 in morphine withdrawal regulation of the brain noradrenergic system. Eur. J. Pharmacol. 430 (2001) 277-281
10. Gellert V.F., and Holtzman S.G. Development and maintenance of morphine tolerance and dependence in the rat by scheduled access to morphine drinking solutions. J. Pharmacol. Exp. Ther. 205 (1978) 536-546
11. 1 receptor antagonist R121919 attenuates the behavioral and endocrine responses to stress. J. Pharmacol. Exp. Ther. 304 (2003) 874-880
12. Hamlin A.S., Buller K.M., Day T.A., and Osborne P.B. Effect of naloxone-precipitated morphine withdrawal on c-fos expression in rat corticotropin-releasing hormone neurons in the paraventricular hypothalamus and extended amygdala. Neurosci. Lett. 362 (2004) 39-43
13. Heinrichs S.C., Menzaghi F., Schulteis G., Koob G.F., and Stinus L. Suppression of corticotropin-releasing factor in the amygdala attenuates aversive consequences of morphine withdrawal. Behav. Pharmacol. 6 (1995) 74-80
14. Houshyar H., Galigniana M.D., Pratt W.B., and Woods J.H. Differential responsivity of the hypothalamic-pituitary-adrenal axis to glucocorticoid negative-feedback and corticotropin releasing hormone in rats undergoing morphine withdrawal: possible mechanisms involved in facilitated and attenuated stress responses. J. Neuroendocrinol. 13 (2001) 875-886
15. Imaki T., Naruse M., Harada S., Chikada N., Imaki J., Onodera H., Demura H., and Vale W. Corticotropin-releasing factor up-regulates its own receptor mRNA in the paraventricular nucleus of the hypothalamus. Brain Res. Mol. Brain Res. 38 (1996) 166-170
16. Iredale P.A., Alvaro J.D., Lee Y., Terwilliger R., Chen Y.L., and Duman R.S. Role of corticotropin-releasing factor receptor-1 in opiate withdrawal. J. Neurochem. 74 (2000) 199-208
17. Keith L.D., Crabbe J.C., Robertson L.M., and Young E.R. Ethanol dependence and the pituitary adrenal axis in mice. II. Temporal analysis of dependence and withdrawal. Life Sci. 33 (1983) 1889-1897
18. Lu L., Liu D., Ceng X., and Ma L. Differential roles of corticotropin-releasing factor receptor subtypes 1 and 2 in opiate withdrawal and in relapse to opiate dependence. Eur. J. Neurosci. 12 (2000) 4398-4404
19. Maj M., Turchan J., Smialowska M., and Przewlocka B. Morphine and cocaine influence on CRF biosynthesis in the rat central nucleus of amygdala. Neuropeptides 37 (2003) 105-110
20. Maldonado R. Participation of noradrenergic pathways in the expression of opiate withdrawal: biochemical and pharmacological evidence. Neurosci. Biobehav. Rev. 21 (1997) 91-104
21. McNally G.P., and Akil H. Role of corticotropin-releasing hormone in the amygdala and bed nucleus of the stria terminalis in the behavioral, pain modulatory, and endocrine consequences of opiate withdrawal. Neuroscience 112 (2002) 605-617
22. Mehta C.R., and Patel N.R. Exact logistic regression: theory and examples. Stat. Med. 14 (1995) 2143-2160
23. Milanes M.V., Laorden M.L., Chapleur-Chateau M., and Burlet A. Alterations in corticotropin-releasing factor and vasopressin content in rat brain during morphine withdrawal: correlation with hypothalamic noradrenergic activity and pituitary-adrenal response. J. Pharmacol. Exp. Ther. 285 (1998) 700-706
24. Owens M.J., Vargas M.A., Knight D.L., and Nemeroff C.B. The effects of alprazolam on corticotropin-releasing factor neurons in the rat brain: acute time course, chronic treatment and abrupt withdrawal. J. Pharmacol. Exp. Ther. 258 (1991) 349-356
25. Pich E.M., Lorang M., Yeganeh M., Rodriguez de Fonseca F., Raber J., Koob G.F., and Weiss F. Increase of extracellular corticotropin-releasing factor-like immunoreactivity levels in the amygdala of awake rats during restraint stress and ethanol withdrawal as measured by microdialysis. J. Neurosci. 15 (1995) 5439-5447
26. Rasmussen K., and Aghajanian G.K. Withdrawal-induced activation of locus coeruleus neurons in opiate-dependent rats: attenuation by lesions of the nucleus paragigantocellularis. Brain Res. 505 (1989) 346-350
27. Rasmussen K., Beitner-Johnson D.B., Krystal J.H., Aghajanian G.K., and Nestler E.J. Opiate withdrawal and the rat locus coeruleus: behavioral, electrophysiological, and biochemical correlates. J. Neurosci. 10 (1990) 2308-2317
28. Rassnick S., Heinrichs S.C., Britton K.T., and Koob G.F. Microinjection of a corticotropin-releasing factor antagonist into the central nucleus of the amygdala reverses anxiogenic-like effects of ethanol withdrawal. Brain Res. 605 (1993) 25-32
29. Richter R.M., and Weiss F. In vivo CRF release in rat amygdala is increased during cocaine withdrawal in self-administering rats. Synapse 32 (1999) 254-261
30. Risbrough V.B., and Stein M.B. Role of corticotropin releasing factor in anxiety disorders: a translational research perspective. Horm. Behav. 50 (2006) 550-561
31. Roberts A.J., Crabbe J.C., and Keith L.D. Genetic differences in hypothalamic-pituitary-adrenal axis responsiveness to acute ethanol and acute ethanol withdrawal. Brain Res. 579 (1992) 296-302
32. Rodriguez de Fonseca F., Carrera M.R.A., Navarro M., Koob G.F., and Weiss F. Activation of corticotropin-releasing factor in the limbic system during cannabinoid withdrawal. Science 276 (1997) 2050-2054
33. Roth R.H., Elsworth J.D., and Redmond D.E. Clonidine suppression of noradrenergic hyperactivity during morphine withdrawal: biochemical studies in rodents and primates. J. Clin. Psychiatry 43 (1982) 42-46
34. Sarnyai Z., Biro E., Gardi J., Vecsernyes M., Julesz J., and Telegdy G. Brain corticotropin-releasing factor mediates 'anxiety-like' behavior induced by cocaine withdrawal in rats. Brain Res. 675 (1995) 89-97
35. Skelton K.H., Nemeroff C.B., Knight D.L., and Owens M.J. Chronic administration of the triazolobenzodiazepine alprazolam produces opposite effects on corticotropin-releasing factor and urocortin neuronal systems. J. Neurosci. 20 (2000) 1240-1248
36. 1 receptor antagonist, R121919, attenuates the neuroendocrine and behavioral effects of precipitated lorazepam withdrawal. Psychopharmacology 192 (2007) 385-396
37. Smagin G.N., Zhou J., Harris R.B., and Ryan D.H. CRF receptor antagonist attenuates immobilization stress-induced norepinephrine release in the prefrontal cortex in rats. Brain Res. Bull. 42 (1997) 431-434
38. Stout S.C., Owens M.J., and Nemeroff C.B. Regulation of corticotropin-releasing factor neuronal systems and hypothalamic-pituitary-adrenal axis activity by stress and chronic antidepressant treatment. J. Pharmacol. Exp. Ther. 300 (2002) 1085-1092
39. Swann A.C., Elsworth J.D., Charney D.S., Jablons D.M., Roth R.H., Redmond Jr. D.E., and Maas J.W. Brain catecholamine metabolites and behavior in morphine withdrawal. Eur. J. Pharmacol. 86 (1982) 167-175
40. Valentino R.J., Foote S.L., and Page M.E. The locus coeruleus as a site for integrating corticotropin-releasing factor and noradrenergic mediation of stress responses. Ann. N. Y. Acad. Sci. 697 (1993) 173-188
41. Zhang T., Feng Y., Rockhold R.W., and Ho I.K. Naloxone-precipitated morphine withdrawal increases pontine glutamate levels in the rat. Life Sci. 55 (1994) PL25-PL31
42. Zhou Y., Spangler R., Ho A., and Kreek M.J. Increased CRH mRNA levels in the rat amygdala during short-term withdrawal from chronic 'binge' cocaine. Brain Res. Mol. Brain Res. 114 (2003) 73-79